{'52WeekChange': -0.48951727,
 'SandP52WeekChange': None,
 'address1': '480 Pleasant Street',
 'address2': 'Suite B300',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 0.76,
 'askSize': 1000,
 'averageDailyVolume10Day': 394637,
 'averageVolume': 870868,
 'averageVolume10days': 394637,
 'beta': 1.35014,
 'beta3Year': None,
 'bid': 0.7222,
 'bidSize': 1100,
 'bookValue': 0.132,
 'category': None,
 'circulatingSupply': None,
 'city': 'Watertown',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 0.759,
 'dayLow': 0.7222,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -2.753,
 'enterpriseToRevenue': 4.48,
 'enterpriseValue': 115781640,
 'exDividendDate': None,
 'exchange': 'NGM',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '617-926-5050',
 'fiftyDayAverage': 0.7854286,
 'fiftyTwoWeekHigh': 2.69,
 'fiftyTwoWeekLow': 0.66,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 81456416,
 'forwardEps': 0.12,
 'forwardPE': 6.0800004,
 'fromCurrency': None,
 'fullTimeEmployees': 84,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.00823,
 'heldPercentInstitutions': 0.53744,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': 1213142400,
 'lastSplitFactor': '1:4',
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/eyepointpharma.com',
 'longBusinessSummary': 'EyePoint Pharmaceuticals, Inc., a specialty '
                        'biopharmaceutical company, develops and '
                        'commercializes ophthalmic products for the treatment '
                        'of eye diseases in the United States and Europe. The '
                        'company provides ILUVIEN for the treatment of '
                        'diabetic macular edema; YUTIQ, a fluocinolone '
                        'acetonide intravitreal implant for intravitreal '
                        'injection for the treatment of chronic non-infectious '
                        'uveitis affecting the posterior segment of the eye; '
                        'DEXYCU, a dexamethasone intraocular suspension, for '
                        'the treatment of post-operative ocular inflammation, '
                        'including treatment following cataract surgery; and '
                        'Retisert, a sustained-release implant for the '
                        'treatment of posterior segment uveitis. It is also '
                        'developing EYP-1901, a 6-month bioerodible Durasert '
                        'Vorolanib tyrosine kinase inhibitor, for the '
                        'treatment of wet age-related macular degeneration, '
                        'diabetic retinopathy, and retinal vein occlusion; and '
                        'YUTIQ50 for the treatment of chronic non-infectious '
                        'uveitis affecting the posterior segment of the eye. '
                        "In addition, the company's development program "
                        'focuses on developing sustained release products '
                        'using its Durasert and Verisome technology platforms '
                        'to deliver drugs to treat chronic diseases. It has '
                        'strategic collaborations with Alimera Sciences, Inc., '
                        'Bausch & Lomb, OncoSil Medical UK Limited, Ocumension '
                        'Therapeutics, and Equinox Science, LLC. The company '
                        'was formerly known as pSivida Corp. and changed its '
                        'name to EyePoint Pharmaceuticals, Inc. in March 2018. '
                        'EyePoint Pharmaceuticals, Inc. was founded in 1987 '
                        'and is headquartered in Watertown, Massachusetts.',
 'longName': 'EyePoint Pharmaceuticals, Inc.',
 'market': 'us_market',
 'marketCap': 91011768,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_4481199',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -50729000,
 'nextFiscalYearEnd': 1640908800,
 'open': 0.7402,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '617-926-5000',
 'previousClose': 0.7402,
 'priceHint': 4,
 'priceToBook': 5.5272727,
 'priceToSalesTrailing12Months': 3.5218546,
 'profitMargins': -1.96304,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 0.759,
 'regularMarketDayLow': 0.7222,
 'regularMarketOpen': 0.7402,
 'regularMarketPreviousClose': 0.7402,
 'regularMarketPrice': 0.7402,
 'regularMarketVolume': 205045,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 124742000,
 'sharesPercentSharesOut': 0.0215,
 'sharesShort': 2680169,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 2853940,
 'shortName': 'EyePoint Pharmaceuticals, Inc.',
 'shortPercentOfFloat': 0.0327,
 'shortRatio': 1.55,
 'startDate': None,
 'state': 'MA',
 'strikePrice': None,
 'symbol': 'EYPT',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -0.464,
 'twoHundredDayAverage': 1.108633,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': '564ca7d9-104b-3085-b6a2-17354e99fc88',
 'volume': 205045,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://eyepointpharma.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '02472'}